ABUS vs KLAC · P/E 5.4, rev $6.2M vs P/E 55, rev $12.16B
Arbutus Biopharma Corp (ABUS) versus KLA Corporation (KLAC) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
KLA Corporation (KLAC) is a semiconductor equipment & materials company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported KLAC revenue for 2025-06-30 was $12.16B. Net income was $4.06B. KLAC currently screens at market cap $252.01B and trailing P/E 54.7.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. KLAC currently screens at market cap $252.01B and trailing P/E 54.7.
Not investment advice. Open the ABUS and KLAC stock pages for the full models.
Not investment advice.